Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5503781 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Extension | EXPERIMENTAL | - |
| Part 1: Drug-drug interaction | EXPERIMENTAL | - |
| Part 2: Relative bioavailability | EXPERIMENTAL | - |
| Part 3: Food effect | EXPERIMENTAL | - |
| Schedule A: RO5503781 QW | EXPERIMENTAL | Participants will receive multiple ascending doses of RO5503781 orally once weekly (QW) x 3 followed by 13 days of rest in a 28 days cycle. |
| Schedule B: RO5503781 QD | EXPERIMENTAL | Participants will receive multiple ascending doses of RO5503781 orally QD x 5 followed by 13 days of rest in a 28 days cycle. |
| Name | Type | Description |
|---|---|---|
| RO5503781 | DRUG | Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design |
| posaconazole | DRUG | Multiple doses Days 8-14 |
Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically or cytologically confirmed advanced malignancies, except all forms of leukemia and lymphoma, for which standard curative or palliative measures do not exist, are no longer effective, or are not acceptable to the patient * M...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
RO5503781 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed by Roche Holding AG for use in oncology. The drug is currently in Phase 1 clinical development.
RO5503781 is a small molecule being developed by Roche Holding AG for oncology indications. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being studied for its potential effects on neoplasms, though its precise mechanism of action is not publicly detailed.
RO5503781 is being developed by Roche Holding AG, a multinational healthcare company. Roche is conducting clinical trials to evaluate the safety and efficacy of this investigational small molecule for the treatment of neoplasms. The company's stock is traded under the ticker RHHBY.
RO5503781 is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total of 160 participants enrolled. The drug is investigational and has not been approved by regulatory authorities. It is being studied for the treatment of neoplasms in oncology.
RO5503781 has been studied in two completed Phase 1 clinical trials. The first, NCT01462175, was a first-in-human study in participants with advanced malignancies except leukemia, enrolling 99 participants across Australia, Canada, France, Netherlands, and South Korea. The second, NCT01901172, studied drug-drug interactions and new formulations in 61 patients with solid tumors in the United States and Canada.
RO5503781 is the primary name used for this investigational drug in clinical trial registrations. No alternative names have been associated with this compound in the available trial information. It is being developed by Roche Holding AG for the treatment of neoplasms.